interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Nedosiran Sodium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Nedosiran Sodium, and who makes it?

Nedosiran Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Nedosiran Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Nedosiran Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Injection

Brand listed, no generic listed as marketed

Brand listed as marketed: Rivfloza. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 11359203 listed to expire 9 October 2035Patent 10738311 listed to expire 9 October 2035Patent 10351854 listed to expire 9 October 2035Patent 11053502 listed to expire 29 October 2035Patent 11661604 listed to expire 12 October 2038Patent 11286488 listed to expire 12 October 2038Exclusivity NPP to 27 March 2028Exclusivity NCE to 29 September 2028Exclusivity ODE-443 to 29 September 2030Exclusivity ODE-531 to 27 March 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 March 2028Exclusivity NPP Rivfloza
  • 29 September 2028Exclusivity NCE Rivfloza
  • 29 September 2030Exclusivity ODE-443 Rivfloza
  • 27 March 2032Exclusivity ODE-531 Rivfloza
  • 9 October 2035Patent 11359203 drug substance
  • 9 October 2035Patent 10738311 drug substance
  • 9 October 2035Patent 10351854 drug substance
  • 29 October 2035Patent 11053502 drug substance
  • 12 October 2038Patent 11661604 drug substance
  • 12 October 2038Patent 11286488 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.